Abstracts tagged "cytokines"

Abstract Number: 1910 • 2012 ACR/ARHP Annual Meeting
Regulation of Microrna 223 Expression in a Gouty Arthritis
Gianina Statache¹, Ashleigh-Ann Rainey¹, Seth Masters², Andra Balanescu³, Iain B. McInnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Immunology Research Centre, Trinity College Dublin, Dublin, United Kingdom, ³Internal Medicine and Rheumatology, University of Medicine and Pharmacy, Bucharest, Romania, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Gout is an inflammatory chronic disease caused by deposition of uric acid crystals in the joint and connective tissues causing pain and disability. Current…
Abstract Number: 1213 • 2012 ACR/ARHP Annual Meeting
The Serum Cytokine Profile of Interstitial Lung Disease in Rheumatoid Arthritis
Jose Felix Restrepo¹, Inmaculada del Rincon², Roy Haas³, Daniel F. Battafarano⁴ and Agustin Escalante⁵, ¹Rheumatology, University of Texas Health Science Center, San Antonio, TX, ²Rheumatology, University Of Texas, Health Science Center, San Antonio, TX, ³Rheumatology, TX, ⁴Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, ⁵Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Interstitial lung disease (ILD) is associated with significant morbidity and mortality in rheumatoid arthritis (RA). There are currently no proven biomarkers for ILD in…
Abstract Number: 673 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Mediators in Individuals with Incomplete Lupus (ILE) in the Lupus Autoimmunity in Relatives (LAUREL) Study
Melissa E. Munroe¹, Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Kathy Moser Sivils⁵, Timothy B. Niewold⁶, Gary S. Gilkeson⁷, Michael H. Weisman⁸, Mariko L. Ishimori⁸, Daniel J. Wallace⁹, David R. Karp¹⁰, John B. Harley¹¹ and Judith A. James¹², ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁷Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a complex autoimmune disease marked by autoantibody production and immune dysregulation. Identification of at-risk populations is essential to minimize morbidity and mortality…
Abstract Number: 1808 • 2012 ACR/ARHP Annual Meeting
Immune Activating Effects of Co-Stimulation of TLR Agonists and Cytokines On Primary and Immortalized Keratinocytes From a Patient with a CARD14 Mediated Pustular Psoriasis (CAMPS) and Healthy Controls
Yongqing Chen¹, Yin Liu², Yan Huang¹, Carole Yee³, Alison MacBride⁴, Anne Bowcock⁵, Michelle Lowes⁶ and Raphaela T. Goldbach-Mansky², ¹Translational Autoinflammatory Disease Section, Office of the Clinical Director NIAMS, Bethesda, MD, ²Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Dermatology Branch, NCI, NIH, Bethesda, MD, ⁴DNA Tumor Virus Section, NIAID, NIH, Bethesda, MD, ⁵Washington University, St. Louis, MO, ⁶Laboratory for Investigative Dermatology, The Rockefeller University, Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY
Background/Purpose: Through producing inflammatory cytokines and chemokines, keratinocytes play an important role along with hematopoietic cells in mediating an inflammatory response in psoriasis and other…
Abstract Number: 1183 • 2012 ACR/ARHP Annual Meeting
Podoplanin-Mediated Interaction of Rheumatoid Arthritis Synovial Fibroblasts with Platelets Modulates IL-8 Expression
Manuel J. Del Rey¹, Elena Izquierdo¹, Regina Faré¹, Alicia Usategui¹, Vanessa Miranda¹, Gabriel Criado², J. D. Cañete³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Unitat d'Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona,, Barcelona, Spain
Background/Purpose: Synovial fibroblasts (SF) are the most abundant resident stromal cells in the synovium. In rheumatoid arthritis (RA), SF expand and undergo phenotypic changes that…
Abstract Number: 645 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European-American Lupus Patients Who Receive Influenza Vaccination
Melissa E. Munroe¹, Jourdan R. Anderson², Joan T. Merrill³, Joel M. Guthridge⁴, Virginia C. Roberts⁴, Gillian M. Air⁵, Linda F. Thompson⁶ and Judith A. James⁷, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Biochemistry, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a multifaceted autoimmune disease denoted by immune dysregulation that contributes to increased morbidity and mortality in part due to infectious complications. Vaccination…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].